Evidence map›Paper›PMID 24814369›Full record

ArticleThe FEBS journal2014

Interactions of disulfide-deficient selenocysteine analogs of μ-conotoxin BuIIIB with the α-subunit of the voltage-gated sodium channel subtype 1.3.

Brad R Green, Min-Min Zhang, Sandeep Chhabra, Samuel D Robinson, Michael J Wilson, Addison Redding, Baldomero M Olivera, Doju Yoshikami, Grzegorz Bulaj, Raymond S Norton

Open access · bronzeAbstract read
In one paragraph

Article in The FEBS journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Brad R GreenMedicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Vic., Australia; Department of Medicinal Chemistry, College of Pharmacy, University of Utah, Salt Lake City, UT, USA.
Min-Min Zhang
Sandeep Chhabra
Samuel D Robinson
Michael J Wilson
Addison Redding
Baldomero M Olivera
Doju Yoshikami
Grzegorz Bulaj
Raymond S Norton
University of Utah · USMonash University · AU

Funding

Venoms, Biological Resources, Molecular BiologyP01GM048677 · NIGMS · UNIVERSITY OF UTAH · PI BANDYOPADHYAY, PRADIP K · 1993 to 2018
$32.2M
NIGMS NIH HHS GM 48677NIGMS NIH HHS P01 GM048677
6 · The paper itself

Abstract

Inhibitors of the α-subunit of the voltage-gated sodium channel subtype 1.3 (NaV 1.3) are of interest as pharmacological tools for the study of neuropathic pain associated with spinal cord injury and have potential therapeutic applications. The recently described μ-conotoxin BuIIIB (μ-BuIIIB) from Conus bullatus was shown to block NaV 1.3 with submicromolar potency (Kd = 0.2 μm), making it one of the most potent peptidic inhibitors of this subtype described to date. However, oxidative folding of μ-BuIIIB results in numerous folding isoforms, making it difficult to obtain sufficient quantities of the active form of the peptide for detailed structure-activity studies. In the present study, we report the synthesis and characterization of μ-BuIIIB analogs incorporating a disulfide-deficient, diselenide-containing scaffold designed to simplify synthesis and facilitate structure-activity studies directed at identifying amino acid residues involved in NaV 1.3 blockade. Our results indicate that, similar to other μ-conotoxins, the C-terminal residues (Trp16, Arg18 and His20) are most crucial for NaV 1 blockade. At the N-terminus, replacement of Glu3 by Ala resulted in an analog with an increased potency for NaV 1.3 (Kd = 0.07 μm), implicating this position as a potential site for modification for increased potency and/or selectivity. Further examination of this position showed that increased negative charge, through γ-carboxyglutamate replacement, decreased potency (Kd = 0.33 μm), whereas replacement with positively-charged 2,4-diamonobutyric acid increased potency (Kd = 0.036 μm). These results provide a foundation for the design and synthesis of μ-BuIIIB-based analogs with increased potency against NaV 1.3.

Indexed as

Amino Acid SequenceAmino Acid SubstitutionAnalgesicsAnimalsCells, CulturedConotoxinsCystineMagnetic Resonance SpectroscopyMembrane PotentialsMolecular Sequence DataNAV1.3 Voltage-Gated Sodium ChannelProtein Structure, SecondarySelenocysteineStructure-Activity RelationshipVoltage-Gated Sodium Channel BlockersXenopus laevisAnalgesicsConotoxinsCystineNAV1.3 Voltage-Gated Sodium ChannelSelenocysteineVoltage-Gated Sodium Channel Blockersconotoxindisulfideneuropathic painselenocysteinevoltage-gated sodium channel

Identifiers

PMID24814369
PMCPMC4160447
OpenAlexW2059461814

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.